Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E62.71 EPS (ttm)6.30 Insider Own0.50% Shs Outstand104.59M Perf Week3.50%
Market Cap41.30B Forward P/E25.86 EPS next Y15.27 Insider Trans-2.14% Shs Float77.33M Perf Month10.57%
Income725.80M PEG3.29 EPS next Q2.62 Inst Own71.50% Short Float5.04% Perf Quarter-2.95%
Sales4.44B P/S9.31 EPS this Y85.10% Inst Trans0.28% Short Ratio4.36 Perf Half Y-16.53%
Book/sh36.10 P/B10.94 EPS next Y41.71% ROA13.70% Target Price468.05 Perf Year-27.12%
Cash/sh8.12 P/C48.64 EPS next 5Y19.09% ROE20.70% 52W Range329.09 - 605.93 Perf YTD-27.26%
Dividend- P/FCF52.02 EPS past 5Y44.90% ROI16.00% 52W High-34.79% Beta1.05
Dividend %- Quick Ratio3.10 Sales past 5Y55.00% Gross Margin90.50% 52W Low20.06% ATR9.97
Employees4300 Current Ratio3.40 Sales Q/Q38.10% Oper. Margin28.90% RSI (14)64.29 Volatility2.25% 2.61%
OptionableYes Debt/Eq0.10 EPS Q/Q118.60% Profit Margin16.40% Rel Volume0.79 Prev Close394.90
ShortableYes LT Debt/Eq0.10 EarningsAug 04 BMO Payout0.00% Avg Volume894.03K Price395.10
Recom2.20 SMA207.15% SMA505.21% SMA200-10.30% Volume57,611 Change0.05%
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Feb-10-16Reiterated Barclays Equal Weight $610 → $425
Feb-09-16Reiterated Piper Jaffray Neutral $607 → $443
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $700 → $525
Jan-25-16Downgrade Chardan Capital Markets Neutral → Sell $525 → $400
Jan-20-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Wells Fargo Outperform
Nov-05-15Reiterated RBC Capital Mkts Outperform $665 → $676
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight $593
Sep-01-15Initiated Raymond James Outperform $615
Jul-25-16 11:05AM  Understanding Improvement in Vertex Pharmaceuticalss PE Multiple
Jul-22-16 07:53PM  Whats Been Beating down the Fidelity Growth Company Fund in 2016?
07:00PM  Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week
04:11PM  Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other
01:12PM  What Do Analysts Recommend for United Therapeutics?
Jul-21-16 03:56PM  Analysts Gauge Alexion Pharmaceuticals Return Potential
Jul-20-16 12:03PM  Why I Bought Shares of Regeneron Pharmaceuticals Inc. Last Week at Motley Fool
Jul-19-16 07:21AM  3 Biotech Stocks to Buy and Hold at Motley Fool
Jul-18-16 04:15PM  Regeneron Pharmaceuticals, Inc. Value Analysis (NASDAQ:REGN) : July 18, 2016
09:30AM  Regeneron Announces Upcoming 2016 Investor Conference Presentation PR Newswire
Jul-13-16 04:31PM  Here's Why Regeneron Pharmaceuticals, Inc. Dropped Another 12% in June at Motley Fool
11:39AM  Biotech: 'We Would Not Be Surprised to See Volatility Continue' at Barrons.com
09:05AM  Regenerons Dupilumab: How Much Potential Does It Hold?
08:30AM  Regeneron Announces 2016 Winners of the Regeneron Prize for Creative Innovation PR Newswire
Jul-12-16 09:06PM  Regenerons Robust Pipeline
02:40PM  5 Stocks Set to Soar on Bullish Earnings
10:20AM  Amgen's Repatha Gains FDA Approval for New Dosing Option
09:27AM  Instant Analysis: Amgen's Latest Approval Raises the Bar Yet Again on Regeneron Pharmaceuticals Inc and Sanofi SA (ADR) at Motley Fool
09:08AM  Whats Driving Regenerons Premium Valuation?
07:00AM  Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease PR Newswire
Jul-11-16 12:06PM  Whats behind Regenerons Operating Efficiency?
09:07AM  Is It Slower Growth for Regenerons Eylea in 2016 and 2017?
08:03AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : July 11, 2016
Jul-08-16 09:25PM  Inside Alnylam Pharmaceuticalss Analyst Recommendations in 2016
03:03PM  Regeneron in 2Q16: How Much Revenue Growth Could It Have?
03:03PM  Regeneron: How Much Upward Potential Does It Have?
09:30AM  Regeneron to Report Second Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2016 PR Newswire
Jul-07-16 04:40PM  Surprise: JNJ Just Did Celgene a Huge Favor
Jul-06-16 04:18PM  Strong Q2 For Biotech Forecast As Drug Prices Keep Going Up
Jul-05-16 01:00AM  Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan PR Newswire
Jul-04-16 09:21AM  3 Top Healthcare Stocks to Buy Now at Motley Fool
Jul-01-16 05:18PM  3 Potential Stock-Moving Drug Events In The Second Half Of 2016
10:02AM  Here's Why Regeneron Pharmaceuticals Inc Is Down 35% This Year at Motley Fool
Jun-29-16 03:24PM  Three Biotech GiantsBut Only Two are Worth Buying at Barrons.com
01:15PM  Esperion Therapeutics Inc Sinks After FDA Says, "Ask Us in 2019" at Motley Fool
12:03PM  Regeneron CEO Schleifer: Drug Pricing Conundrum
10:24AM  Drug Companies Need to Tell a Better Story, Regeneron Says at Bloomberg
10:24AM  Drug Companies Need to Tell a Better Story, Regeneron CEO Says
06:08AM  Coverage initiated on Regeneron Pharma by Bernstein
Jun-28-16 04:31PM  Novartis, Xencor Ink $2.4 Billion Licensing Deal In Blood Cancer
Jun-27-16 09:42PM  The Largest Drug Pipelines Will Surprise You
12:55PM  Regeneron acquires Pitney Bowes building in Rensselaer Tech Park at bizjournals.com
Jun-25-16 02:01PM  3 Biotech Stocks to Buy Now for the Long Haul at Motley Fool
12:20AM  [$$] Biotech Labs Birth New Drugsand New Fortunes at The Wall Street Journal
Jun-24-16 04:34PM  How Does Brexit Affect Biotech Stocks? Wall Street Weighs In
Jun-23-16 10:10AM  Company News for June 23, 2016
Jun-22-16 04:57PM  Medicare 'Death Panel' Is On Ice; Biotechs Rally
04:04PM  Verifone, Biogen Crash Wednesdays 52-Week Low Club at 24/7 Wall St.
03:56PM  Regeneron Tries to Recover From Lows
12:51PM  Stocks Erased Gains; Biotechs, KB Home Jump As Tesla Dives
10:50AM  Biotech: Why Take the Risk? at Barrons.com
Jun-21-16 06:14PM  This Is the Most Important Business Trend in Pharma at Fortune
04:43PM  Why Biotech is Getting Crushed at Barrons.com
Jun-20-16 05:07PM  5 Of The Hottest Stocks To Own During The Summer
Jun-17-16 04:10PM  Cisco, Regeneron, Skyworks, Skechers Lead Insider Trades
10:14AM  More Fovista Risk For Regeneron Than Investors Realize: Canaccord at Barrons.com
Jun-15-16 06:07AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-14-16 04:44PM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
04:20PM  3 Biotech Stocks to Buy If the Market Crashes at Motley Fool
11:01AM  Regeneron: Nine Reasons Praluent Could Be Forced From the US Market at Barrons.com
Jun-13-16 12:05PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : June 13, 2016
09:00AM  5 Top Stocks to Buy in June at Motley Fool
Jun-10-16 09:00PM  Should You Listen to the Rich?: Jim Cramer's Best Blogs
01:15PM  4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
07:00AM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
Jun-09-16 08:17PM  UPDATE: Biotech Stocks: Much Ado About Nothing at ASCO? at Barrons.com
04:40PM  Why Ophthotech Corp. Shares Soared 14.9% in May at Motley Fool
05:01AM  The X-Men Approach to Medicine at Bloomberg
Jun-08-16 02:21PM  What Helped Incyte Report Growth in 1Q16?
11:33AM  Biotech Stocks: Wait Until Next Year at Barrons.com
Jun-06-16 09:52AM  Regeneron, Sanofi Report Positive Dupilumab Phase III Data
01:27AM  Sanofi and Regeneron report positive skin disease trial Reuters
01:00AM  Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients PR Newswire
Jun-03-16 02:18PM  Biotech: What's the Trade? at Barrons.com
Jun-02-16 10:23AM  Biotech Stocks: Don't Expect a 'Miraculous Recovery' at Barrons.com
Jun-01-16 01:40PM  Regeneron: Coming Into Its Own at Barrons.com
10:00AM  Regeneron Reports Interim Data on Cholesterol Lowering Drug
May-31-16 07:00PM  Jim Cramer's 'Mad Money' Recap: How to Handle Your Finances at Any Age
06:46PM  How to Discover the Best Biotechs in the World
12:01PM  Regeneron Presents Favorable Interim Data From Stage 2 Proof-Of-Concept Trial Of Evinacumab
09:00AM  Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia PR Newswire
12:07AM  New Eczema Treatments Could Be Available Soon at The Wall Street Journal
May-27-16 03:00PM  The 'Nobel Prize of high school competitions' just got the most money it's received in a century from a biotech giant
08:22AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche at Motley Fool
May-26-16 08:30AM  Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search PR Newswire
12:12AM  [$$] Regeneron Named as Science Talent Search Sponsor at The Wall Street Journal
12:01AM  [$$] Regeneron Named as Science Talent Search Sponsor at The Wall Street Journal
12:00AM  Biotech Regeneron replaces Intel as sponsor of Science Talent Search
May-25-16 09:16PM  [$$] Biotech Named as Sponsor at The Wall Street Journal
May-24-16 06:04PM  Lilly says new type of pain drug could lessen need for opioids Reuters
12:24PM  Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why at Motley Fool
09:03AM  How I Made a Huge Profit on Regeneron -- And It was One of My Biggest Mistakes Ever
May-23-16 07:44PM  Sanofi Is Shuffling Its Exec Roster Amid Continued Struggles at Fortune
May-19-16 02:40PM  Why Albany added 1,400 private sector jobs instead of losing 800 at bizjournals.com
May-18-16 01:30PM  History Says Now Is The Time To Buy This Biotech Firm
12:02PM  Regeneron Pharmaceuticals (REGN) Stock is the 'Chart of the Day' at TheStreet
May-17-16 05:54PM  After-hours buzz: Alphabet, LendingClub, Target & more at CNBC
05:54PM  After-hours buzz: Alphabet, LendingClub, Target & more at CNBC
05:43PM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Ophthotech at Motley Fool
11:57AM  IBBs Large Caps: Regeneron Pharmaceuticals Rose 6%
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema, as well as macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of low-density lipoprotein cholesterol; and ARCALYST for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. The company is also developing trap-based clinical product EYLEA for the treatment of Neovascular Glaucoma; antibody-based clinical products comprising Praluent, Sarilumab, Dupilumab, REGN2810, REGN2176-3, Fasinumab, REGN2222, Evinacumab, REGN1033, REGN1908-1909, REGN1979, and Nesvacumab/aflibercept; and ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer. It has collaborations with Sanofi, Bayer HealthCare, and Mitsubishi Tanabe Pharma Corporation for the development of antibody-based clinical based products. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RYAN ARTHUR FDirectorMay 24Sale396.641,000396,64039,500May 25 04:02 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 18Sale385.774,4131,702,4031,921May 19 04:26 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 17Option Exercise30.639,460289,76011,381May 19 04:26 PM
VAGELOS P ROYChairman of the BoardMay 12Option Exercise20.32230,6844,687,499563,564May 13 04:40 PM
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorMar 21Option Exercise177.822,000355,64016,000Mar 21 04:27 PM
GOLDSTEIN JOSEPH LDirectorMar 21Sale375.002,000750,00014,000Mar 21 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Option Exercise52.033,954205,72710,820Dec 29 07:44 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Sale552.083,9542,182,9246,866Dec 29 07:44 PM
Aberman Michael SSVP Strategy Investor RelationDec 17Option Exercise24.004,00096,00016,498Dec 18 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise52.031,92199,95017,742Dec 18 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise52.031,92199,9506,866Dec 18 04:28 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise52.031,92199,950501,921Dec 18 04:26 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 16Option Exercise52.031,92199,9501,921Dec 18 04:27 PM
STAHL NEILEVP Research and DevelopmentDec 16Option Exercise52.031,92199,95027,594Dec 18 04:27 PM
BROWN MICHAEL SDirectorDec 10Option Exercise177.823,000533,4603,000Dec 11 04:14 PM
BROWN MICHAEL SDirectorDec 10Sale546.453,0001,639,3650Dec 11 04:14 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 02Sale549.0343,34823,799,539500,000Dec 04 04:13 PM
SING GEORGE LDirectorNov 18Option Exercise19.693,00059,070115,772Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.00500290,0004,500Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.003,0001,740,000112,772Nov 20 04:04 PM
VAGELOS P ROYChairman of the BoardNov 18Sale587.9017,24010,135,312334,611Nov 19 04:20 PM
STAHL NEILEVP Research and DevelopmentNov 09Sale560.0522,10112,377,55922,029Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 06Sale563.0020,00011,260,06844,130Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 05Option Exercise28.29100,0002,828,50097,029Nov 09 05:10 PM
VAGELOS P ROYChairman of the BoardNov 03Sale580.233,9852,312,217351,851Nov 04 04:05 PM
VAGELOS P ROYChairman of the BoardNov 02Sale580.1813,2577,691,446355,836Nov 04 04:05 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriNov 02Sale571.6143,34824,778,125543,348Nov 03 04:20 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriOct 30Option Exercise11.64182,8182,128,002682,818Nov 03 04:20 PM
BROWN MICHAEL SDirectorSep 21Option Exercise57.113,000171,3303,000Sep 22 02:39 PM
BROWN MICHAEL SDirectorSep 21Sale551.553,0001,654,6500Sep 22 02:39 PM
BAKER CHARLES ADirectorSep 17Option Exercise18.615,00093,05014,000Sep 18 04:06 PM
BAKER CHARLES ADirectorSep 17Sale550.005,0002,750,0009,000Sep 18 04:06 PM
SCHLEIFER LEONARD SPresident & CEOSep 02Option Exercise402.697,2262,909,83849,313Sep 03 04:59 PM
LAROSA JOSEPH JSVP General Counsel and SecretSep 01Option Exercise59.201,68999,98916,756Sep 02 04:04 PM
Powchik PeterSVP Clinical Development & RegAug 14Sale573.3823,48513,465,86615,821Aug 17 04:01 PM
Powchik PeterSVP Clinical Development & RegAug 13Option Exercise117.3360,3617,082,07046,299Aug 17 04:01 PM
POON CHRISTINE ADirectorAug 12Sale564.1611263,186790Aug 12 04:45 PM
POON CHRISTINE ADirectorAug 11Option Exercise273.67470128,6251,125Aug 12 04:45 PM
GILMAN ALFRED GDirectorAug 06Option Exercise57.115,000285,55013,912Aug 07 06:15 PM
GILMAN ALFRED GDirectorAug 06Sale587.125,0002,935,6018,912Aug 07 06:15 PM
Terifay Robert JSVP CommercialAug 06Sale588.9713,4237,905,78123,293Aug 07 06:14 PM
Terifay Robert JSVP CommercialAug 05Option Exercise30.6332,500995,47552,529Aug 07 06:14 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Option Exercise270.435,0001,352,1509,745Aug 05 08:58 PM
Landry Robert ESVP Finance & CFOAug 05Option Exercise272.704,0001,090,80011,099Aug 06 09:00 PM
Tessier-Lavigne MarcDirectorAug 05Option Exercise57.115,000285,5506,187Aug 05 08:55 PM
Landry Robert ESVP Finance & CFOAug 05Sale592.844,0002,371,3507,099Aug 06 09:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Sale585.535,0002,927,6484,945Aug 05 08:58 PM
Tessier-Lavigne MarcDirectorAug 05Sale590.265,0002,951,2751,187Aug 05 08:55 PM
GOLDSTEIN JOSEPH LDirectorAug 04Sale586.002,0001,172,00014,000Aug 05 10:03 AM